Teicoplanin Formulation Producers and Teicoplanin Formulation Market Trend

Teicoplanin is an antibiotic used to treat severe bacteremia, complicated skin and soft tissue infections, bone and joint infections, infective endocarditis, peritonitis, community-acquired pneumonia, and community-acquired urinary tract infections. Due to its efficacy and low cytotoxicity, teicoplanin has also been used for patients with complications, including pediatric and immunocompromised patients.

The global Teicoplanin Formulation market size was USD 248 million in 2017, growing to USD 209 million in 2022, with a CAGR of -3.4% from 2017 to 2022. The global Teicoplanin Formulation market size is expected to reach USD 219 million in 2027, with a CAGR of 0.9% from 2022 to 2027.

Figure 2017-2027 Global Teicoplanin Formulation Market Size (Million USD) and CAGR
The global Teicoplanin Formulation market is dominated by Sanofi holding 45% of the market share, followed by other companies such as Glenmark, Kolmar Korea, and Zhejiang Medicine, each accounting for less than 10% volume share in the same year.
Currently, APAC is the largest Teicoplanin Formulation production region accounting for 47% volume share, followed by comparable production in Europe market accounting for 46% volume share.
Teicoplanin formulations are available in injection solution and injection powder for solution.